AllSci News
Summit expands ivonescimab's challenge to Keytruda into bladder cancer
Summit Therapeutics (Nasdaq: SMMT) announced the initiation of HARMONi-GU1, a Phase II/III trial testing ivonescimab plus Astellas/Pfizer's Padcev...
Takeda ushers in the orexin era with landmark FDA approval
The US FDA has approved Orzeyful (oveporexton) for the treatment of narcolepsy type 1 (NT1) in adults, marking the first approval of an orexin receptor...
Lexeo's PKP2 cardiomyopathy gene therapy adds RMAT status
New York-based Lexeo Therapeutics (Nasdaq: LXEO) announced that the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to LX2020,...
Moderna's mFlusiva becomes first mRNA influenza vaccine in US
The US FDA has approved Mflusiva (mRNA-1010), Cambridge, Massachusetts-based Moderna's (Nasdaq: MRNA) mRNA-based seasonal influenza vaccine, for active...
FAST taps Apertura's BBB-crossing AAV platform to advance Angelman gene therapy
The Foundation for Angelman Syndrome Therapeutics (FAST) has entered an agreement with New York-based Apertura Gene Therapy to access TfR1 CapX, a...
Eton taps China's Auson gel timolol for infantial hemangiomas
Deer Park, Illinois-based Eton Pharmaceuticals (Nasdaq: ETON) has licensed U.S. rights to ASN-001, a topical timolol gel for proliferating superficial...
CSPC and AstraZeneca establish biologics manufacturing joint venture in China
CSPC Pharmaceutical Group Limited (HKEX: 01093) and AstraZeneca announced a joint venture contract to construct and operate a new-generation biologics...
Attovia completes upsized IPO for USD 289m take-home
San Carlos, California-based Attovia Therapeutics, Inc. (Nasdaq: ATTO), a clinical-stage immunology company whose biparatopic biologics platform has...
Expedition raises USD 115m to advance Fosun-sourced DPP1 inhibitor
San Francisco-based Expedition Therapeutics has closed an oversubscribed USD 115 million Series B financing round to advance its lead asset, EXPD-101...
Mironid raises USD 46m to advance first-in-class ADPKD therapy
Glasgow-based Mironid has raised USD 46 million in a Series B round to advance the clinical development of its lead small molecule candidate for autosomal...
Alteogen lands third ALT-B4 license deal with undisclosed partner, up to USD 365m total
South Korea-based Alteogen Inc. (KOSDAQ: 196170) has signed an exclusive license agreement with an undisclosed global pharmaceutical company, granting...
Marengo nominates first TriSTAR candidate under USD 1.2b Ipsen collaboration
Marengo Therapeutics has nominated its first development candidate under its TriSTAR collaboration with Ipsen (Euronext: IPN), triggering milestone payments...
Adneuris licenses cebranopadol to Maruishi in second ex-US deal within four weeks
Adneuris Therapeutics has granted Japan-based Maruishi Pharmaceutical Co., Ltd. an exclusive license to develop and commercialize cebranopadol, a...
Gilead Q2'26: BIC/LEN nears approval as weekly HIV pipeline expands
Gilead Sciences Q2 2026 earnings call, held on August 4, 2026, centered on three near-term binary events — an FDA decision on bictegravir plus lenacapavir...
Amgen Q2'26: MariTide strategy sharpens as AMG 513 exits pipeline
Amgen (Nasdaq: AMGN) held its Q2 2026 earnings call on August 4, 2026, with the most consequential pipeline disclosures centered on three decisions: the...
The AllSci Brief
Free, systematic R&D and deal news. Daily.